Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells. It exhibits potent activity against these targets, with IC50 values of 2.26 μM for both. Moreover, FLT3-IN-13 induces cell cycle arrest at the G2/M phase and promotes apoptosis. Notably, it displays considerable anticytotoxic activity, specifically against leukemia [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 349,000 |
50 mg | 約10-14 週間 | ¥ 454,500 |
100 mg | 約10-14 週間 | ¥ 574,000 |
説明 | FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells. It exhibits potent activity against these targets, with IC50 values of 2.26 μM for both. Moreover, FLT3-IN-13 induces cell cycle arrest at the G2/M phase and promotes apoptosis. Notably, it displays considerable anticytotoxic activity, specifically against leukemia [1]. |
In vitro | FLT3-IN-13 (compound 20) exhibits potent antiproliferative effects against HL-60 cells, with an IC50 value of 0.48 ± 0.08 μM [1]. It induces cell cycle arrest at the G2/M phase, manifested by changes in cell cycle distribution (G1%: 24.76±1.00, S%: 21.26±1.72, G2%: 32.78±2.21) and triggers apoptosis with an early-apoptosis rate of 6.13±1.20% and late-apoptosis of 13.06±0.40% [1]. Additionally, FLT3-IN-13 significantly upregulates the expression of P53, TNFα, and caspase 3/7 proteins, alongside increasing the Bax/Bcl-2 ratio in HL-60 cells, delineating its mechanism of action in inducing apoptotic cell death [1]. |
分子量 | 342.35 |
分子式 | C20H14N4O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FLT3-IN-13 Inhibitor inhibitor inhibit